Biogen (BIIB) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Strategic focus and operational changes

• Leadership and board changes have led to a renewed focus on shareholder returns and cost management.

• Efforts are underway to halt revenue decline, manage costs through a savings program, and return to top-line growth.

• Portfolio is being augmented with lower-risk, more traditional programs, such as the HI-Bio acquisition, to balance risk.

• Cost reduction initiatives, including the Fit for Growth program, have cut waste and redeployed resources to growth areas.

• Internal alignment and a culture of ownership are emphasized to drive value for both patients and shareholders.

Product launches and market dynamics

• Leqembi's launch has required building new market infrastructure and awareness, leading to a slower, steady growth curve rather than rapid acceleration.

• Majority of early Leqembi prescriptions are from unaffiliated doctors, but integrated delivery networks are expected to become the main drivers over time.

• Physician experience and patient outcomes are gradually increasing receptivity and confidence in Leqembi.

• The introduction of Kisunla by Lilly is seen as expanding the market rather than threatening share, with both products expected to coexist.

Regulatory and pipeline updates

• A negative CHMP opinion in Europe for Leqembi is being addressed through a reexamination process, with a decision expected in fiscal Q4.

• Efforts are being made to include three-year extension data in the European review, though acceptance is uncertain.

• Subcutaneous (sub-Q) formulations of Leqembi are in development, with maintenance filing expected by October and induction filing targeted for early next year.

• Sub-Q options are anticipated to improve patient experience and align with emerging blood-based biomarkers.